Translational pharmacology supporting biologics development in Oncology

Translational Pharmacology is responsible for connecting products of novel molecular research, such as Biologics, to the patients that need it. Learn more here.

Lewis acid catalyzed chemoselective and regioselective epoxide ring opening with sulfoximines

We report Sulfoximines with the first regioselective Epoxide Ring opening; these findings broaden their Drug Discovery and design applications. Read more.

In vitro pharmacological profile of Compound A

Strong genetic evidence has validated Leucine-Rich Repeat Kinase 2 (LRRK2) as a target of interest for Parkinson’s Disease.

In vivo PK/PD profile of Compound A

Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are the most common genetic cause of Parkinson’s disease, leading to the development of LRRK2 inhibitors as potential therapeutic approach. Among them, Compound A has recently been selected as a potent, selective and brain-penetrant LRRK2 inhibitor.

Lead optimization of radiopharmaceuticals for molecular radiotherapy and preclinical evaluation

Get to know more about lead optimization of radiopharmaceuticals for molecular radiotherapy and preclinical evaluation!

Mouse models of hepatocellular carcinoma

Get to know more about our comprehensive & functional preclinical platform for immunotherapy research using mouse models (PDX, human transgenic mouse).

Using individual or a consortium of bacteria for immuno-oncology research

Get to know more about the beneficial role of bacteria for cancer therapy. Oncodesign Services, vector Of Innovation in oncology, inflammation & Covid-19.

Scientific Posters | AACR 2022

Find all 4 posters that are presented during AACR 2022. They unveil our expertise in oncology using our scientific know-how (medicinal chemistry, radio-imaging, in vivo model and microbiome)

Structure-Based Design of small macrocyclic CDK9 degraders as chemical biology tools and beyond

With small macrocyclic “probes” from our proprietary library in the low nanomolar range IC50, we turned our attention to CDK9 inhibitors with good selectivity profile against CDK1/2/5/7 as a starting point for building bifunctional small macrocyclic kinase degraders.

Animal models for novel therapies on fibrosis and NASH

Discovery of Novel Inhibitors of PIM-1 Kinase Enabled by Generative AI

Use generative AI to generate and identify new PIM-1 kinase inhibitor hits with activity, freedom-to-operate, and good in vitro ADME properties.

Pharmacokinetic and Biodistribution of Formatted Affimer® Biotherapeutics Targeting PD-L1

Programmed Cell Death-Ligand 1 (PD-L1) is part of the immune checkpoint system involved in preventing autoimmunity. PD-L1 is upregulated on tumors cells and binds to its receptor, PD-1, expressed by immune cells in the tumor microenvironment.